Patents by Inventor Hrissanthi Ikonomidou

Hrissanthi Ikonomidou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
    Patent number: 7452875
    Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: November 18, 2008
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski
  • Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
    Patent number: 7427611
    Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: September 23, 2008
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski
  • Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
    Patent number: 7410962
    Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: August 12, 2008
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski
  • Amidomethyl-Substituted 1-(Carboxyalkyl) Cyclopentyl-Carbonylamino-Benzazepine-N-Acetic Acid Compounds, Process and Intermediate Products for Their Preparation and Pharmaceutical Compositions Containing Them
    Publication number: 20080085889
    Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
    Type: Application
    Filed: August 3, 2007
    Publication date: April 10, 2008
    Applicant: SOLVAY PHARMACEUTICALS GmbH
    Inventors: Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski
  • AMIDOMETHYL-SUBSTITUTED 1-(CARBOXYALKYL) CYCLOPENTYL-CARBONYLAMINO-BENZAZEPINE-N-ACETIC ACID COMPOUNDS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20070265244
    Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
    Type: Application
    Filed: July 3, 2007
    Publication date: November 15, 2007
    Applicant: SOLVAY PHARMACEUTICALS GmbH
    Inventors: Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski
  • Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
    Patent number: 7262184
    Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: August 28, 2007
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski
  • Use of glutamate antagonists for the treatment of cancer
    Patent number: 7247610
    Abstract: Disclosed are methods for treating cancer by administering an inhibitor of the interaction of glutamate with the KA receptor complex.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: July 24, 2007
    Inventor: Hrissanthi Ikonomidou
  • Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
    Patent number: 7232813
    Abstract: The invention relates to a novel use of known benzazepine, benzoxazepine, benzo-thiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders. The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formulae (1): wherein the symbols have the meanings as given above in the description.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: June 19, 2007
    Assignee: Solvay Pharmaceuticals B.V.
    Inventors: Hrissanthi Ikonomidou, Lechoslaw A. Turski, Dieter Ziegler, Michael Weske
  • Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
    Publication number: 20060281732
    Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
    Type: Application
    Filed: April 17, 2006
    Publication date: December 14, 2006
    Applicant: Solval Pharmaceuticals GmbH
    Inventors: Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski
  • Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
    Publication number: 20050153936
    Abstract: The invention relates to a novel use of known benzazepine, benzoxazepine, benzo-thiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders. The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formulae (1): wherein the symbols have the meanings as given above in the description.
    Type: Application
    Filed: January 7, 2005
    Publication date: July 14, 2005
    Inventors: Hrissanthi Ikonomidou, Lechoslaw Turski, Dieter Ziegler, Michael Weske
  • Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
    Publication number: 20050119247
    Abstract: Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula 1, wherein the substituents R1, R2, R3 and R4 have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
    Type: Application
    Filed: September 24, 2004
    Publication date: June 2, 2005
    Applicant: Solvay Pharmaceuticals GmbH
    Inventors: Dagmar Hoeltje, Yvan Fischer, Dieter Ziegler, Michael Weske, Katrin Michaelis, Yasmin Karimi-Nejad, Josef Messinger, Axel Pahl, Constanze Hoefer, Hrissanthi Ikonomidou, Lechoslaw Turski
  • Use of glutamate antagonists for the treatment of cancer
    Publication number: 20050054650
    Abstract: Disclosed are methods for treating cancer by administering an inhibitor of the interaction of glutamate with the NMDA/glycine/polyamine receptor/ion channel complex.
    Type: Application
    Filed: August 6, 2004
    Publication date: March 10, 2005
    Inventor: Hrissanthi Ikonomidou
  • Use of glutamate antagonists for the treatment of cancer
    Publication number: 20050054619
    Abstract: Disclosed are methods for treating cancer by administering an inhibitor of the interaction of glutamate with the KA receptor complex.
    Type: Application
    Filed: August 6, 2004
    Publication date: March 10, 2005
    Inventor: Hrissanthi Ikonomidou
  • Use of glutamate antagonists for the treatment of cancer
    Patent number: 6797692
    Abstract: Glutamate antagonists (NMDA, AMPA and kainate receptor antagonists) and their physiologically compatible salts can be used for the preparation of drugs for treatment of cancer.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: September 28, 2004
    Inventor: Hrissanthi Ikonomidou